Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human leukocyte antigen A*02:01 (HLA-A*02:01) is a specific allele of the HLA-A gene encoding an MHC class I molecule on chromosome 6p21.3. It forms a heterodimer with β2-microglobulin, featuring a peptide-binding groove between antiparallel α1 and α2 helices supported by an eight-stranded β-sheet, plus an α3 domain for CD8 binding. It presents endogenous peptides (typically 8-10 mers with anchors like Val at P2 and Leu/Val at C-terminus) to CD8+ T cells for adaptive immunity. Polymorphisms in pockets A-F determine peptide specificity, e.g., preferring L/M/I at P2 and V/L/I/A at PΩ. Common in populations, it influences viral clearance (e.g., HCV, HIV), cancer immunotherapy, and transplant matching, with crystal structures confirming typical MHC class I fold (e.g., RMSD 0.415 Å to other complexes).
Peptide binding in antigen-binding groove for T cell receptor recognition, Safety switch in CAR-T therapy via allelic specificity
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human leukocyte antigen A*02:01 (HLA-A*02:01) (HLA-A*02:01).